Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SH3PXD2A antisense RNA 1 (SH3PXD2A-AS1) is a long non-coding RNA transcribed antisense to the SH3PXD2A gene. Located on chromosome 10, SH3PXD2A-AS1 is about 2023 base pairs in length. It is strongly upregulated in various cancers, such as colorectal cancer and non-small cell lung cancer, where it promotes cell cycle progression, proliferation, and tumor growth. Mechanistically, it interacts with protein partners such as DHX9 (to regulate FOXM1 expression) and p53 (to regulate p53 target genes), impacting oncogenic processes and cell fate decisions. In preeclampsia, SH3PXD2A-AS1 inhibits trophoblast invasion by recruiting CTCF to promoters and suppressing gene transcription. While not a classical receptor or enzyme, its emerging roles as an oncogenic lncRNA and disease biomarker make it a candidate for future RNA-based therapies in precision medicine.
No approved drugs yet; mechanisms include modulation of cell cycle and proliferation via RNA interference or future lncRNA-targeting approaches.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on SH3PXD2A antisense RNA 1 (SH3PXD2A-AS1).